The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study.
Almuradova E, Seyyar M, Arak H, Tamer F, Kefeli U, Koca S, Sen E, Telli TA, Karatas F, Gokmen I, Turhal NS, Sakalar T, Ayhan M, Ekinci F, Hafizoglu E, Kahraman S, Kesen O, Unal C, Alan O, Celik S, Yekeduz E, Omur O, Gokmen E.
Almuradova E, et al. Among authors: tamer f.
Int J Cancer. 2024 Feb 15;154(4):692-700. doi: 10.1002/ijc.34749. Epub 2023 Oct 11.
Int J Cancer. 2024.
PMID: 37818966